



03 0102

COFCR
#

CASE 4-20921/A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 041586660 US
Express Mail Label NumberFebruary 27, 2002
Date of DepositMCW

16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

WAGNER ET AL.

U.S. Patent No.: 6,294,197 B1

ISSUED: September 25, 2001

FOR: SOLID ORAL DOSAGE FORMS OF VALSARTAN

CERTIFICATE

MAR 13 2002

OF CORRECTION

Attention: Certificate of Corrections BranchAssistant Commissioner for Patents
Washington, D.C. 20231Request for Certificate of Correction under CFR § 1.322

Sir:

Pursuant to 37 CFR 1.322, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent 6,294,197 B1 containing the corrections set forth on the appended Form PTO 1050.

The errors in the table immediately below are believed to be attributable to the Patent and Trademark Office:

Location and Error in Printed Patent	Location of support in Specification or Amendment
Page 1 , line 1 of Abstract, insertion of "oral" after "solid" Page 1 , line 2 of Abstract, insertion of "an active agent selected from" after "a)"	Specification filed May 7, 1999, page 23
Column 5 , line 52, replace "0 μ " with -- 0.1 μ --.	Specification filed May 7, 1999, page 9, line 12 of text
Column 9 , Example 3, table, insertion of line between "Magnesium Stearate" and "AVICEL PH-301"	Specification filed May 7, 1999, page 16, Example 3

Location and Error in Printed Patent	Location of support in Specification or Amendment
Column 10 , line 31, (line 1 of claim 2), insertion of "compressed" after "A:" and before "solid".	Amendment, dated July 27, 2000, page 2, line 7 of text
Column 11 , line 50, (line 4 of claim 26), insertion of "stroke" between "disease" and "left ventricular".	Amendment, dated July 27, 2000, page 4, line 23 of text
Column 11 , line 53, (line 7 of claim 26), insertion of -- compressed before "solid" and deletion of "oral" between "solid" and "dosage".	Amendment, dated July 27, 2000, page 4, line 25 of text
Column 11 , line 54, (line 8 of claim 26), substitution of "said" with "such".	Amendment, dated July 27, 2000, page 4, line 26 of text (last line)

In addition, Applicants would like to correct the following typographical errors ascribable to the Applicants:

Location and Error in Printed Patent (ascribable to Applicants)
Column 6 line 15, replace "rapind" with --rapid--. line 49, replace "seive" with --sieve--.
Column 10 line 42, (claim 5, line 1) replace "from" with --form--. line 44, (claim 6, line 1) replace "from" with --form--.
Column 11 line 7, (claim 14, line 1) replace "from" with --form--. line 56, (claim 29, line 1) replace "from" with --form--.

Attached is a duplicate of Form PTO 1050, with at least one copy being suitable for printing.


A fee required by 37 C.F.R. § 1.20(a) in the amount of \$100 is believed to be necessitated by this Request for Certificate of Correction. Please charge said fee to Deposit Account No. 19-0134 in the name of Novartis Corporation. The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Please send the Certificate of Correction to the address currently associated with Customer
No. 001095, viz.:

Thomas Hoxie
Novartis Corporation
Patent and Trademark Department
564 Morris Avenue
Summit, New Jersey 07901-1027

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6807



Diane Tso
Attorney for Applicants
Reg. No. 46,012

Date: February 27, 2002